Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis

Julian D Gillmore; Rodney H Falk; Mathew S Maurer; Mazen Hanna; Verena Karsten; John Vest; Jared Gollob; Philip N Hawkins

首页> 外文期刊>Orphanet journal of rare diseases >Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis

【24h】

Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis

机译：Revusiran的2期开放标签扩展（OLE）研究，一种研究性的RNAi治疗药物，用于治疗甲状腺素转甲状腺素蛋白淀粉样变性病

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Orphanet journal of rare diseases》 |2015年第s1期|共页
作者
Julian D Gillmore; Rodney H Falk; Mathew S Maurer; Mazen Hanna; Verena Karsten; John Vest; Jared Gollob; Philip N Hawkins;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类全身性疾病;
关键词

相似文献

外文文献
中文文献
专利

1. PHASE 2 OPEN-LABEL EXTENSION (OLE) STUDY OF PATISIRAN, AN INVESTIGATIONAL RNA INTERFERENCE (RNAI) THERAPEUTIC FOR THE TREATMENT OF HEREDITARY ATTR AMYLOIDOSIS WITH POLYNEUROPATHY [J] . Adams D., Coelho T., Conceicao E., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：Patisiran的第2阶段开放标签延伸（OLE）研究，一种调查RNA干扰（RNAi）治疗遗传性遗传素邻近的遗传素
2. LONG-TERM USE OF PATISIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS: 12 MONTH EFFICACY AND SAFETY FROM GLOBAL OPEN LABEL EXTENSION STUDY [J] . Gonzalez-Duarte Alejandra, Coelho Teresa, Adams David, Muscle and Nerve . 2018,第S2期

机译：长期使用Patisiran，一种调查rnai治疗，遗传性的Transthyretin介导的淀粉样蛋白症的患者：全球开放标签扩展研究的12个月疗效和安全性
3. PHASE 2 OPEN-LABEL EXTENSION STUDY OF PATISIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF FAMILIAL AMYLOID POLYNEUROPATHY [J] . Adams David, Suhr Ole, Conceicao Isabel, Journal of Neurology, Neurosurgery and Psychiatry . 2015,第11期

机译：帕西西兰（PATISIRAN）的2期开放式扩展研究，这是一种用于治疗家族性淀粉样变性神经病变的RNAi治疗药物
4. Patient-Specific Biomechanical Modeling of Cardiac Amyloidosis - A Case Study [C] . D. Chapelle, A. Felder, R. Chabiniok, International conference on functional imaging and modeling of the heart . 2015

机译：特定患者心脏淀粉样变性的生物力学建模-案例研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Phase 2 open-label extension (OLE) study of revusiran an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis [O] . Julian D Gillmore, Rodney H Falk, Mathew S Maurer, 2015

机译：Revusiran的2期开放标签扩展（OLE）研究一种研究性RNAi治疗药物用于治疗甲状腺甲状腺激素转甲状腺素样淀粉样变性病
7. Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis [O] . 2015

机译：Revusiran的2期开放标签扩展（OLE）研究，一种研究性RNAi治疗药物，用于治疗甲状腺甲状腺素转基因蛋白淀粉样变性病

Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis

著录项

相似文献

相关主题

期刊订阅